IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating.
Company: BioAmber Inc.
Symbol: BIOA
Price: Last trade $10.51
Trade Date: 5/1
Shares: 3.3 million
Underwriter(s) Canaccord Genuity, Barclays
Co Manager(s) Raymond James, SG Americas Securities
Rating=Subscription Needed
Company: TetraLogic Pharmaceuticals Corporation
Symbol: TLOG
Price: Last trade $4.32
Trade Date: 5/1
Shares: 5.8 million
Underwriter(s) William Blair & Co., Nomura Securities Int’l
Rating=Subscription Needed
Company: NephroGenex
Symbol: NRX
Price: Last trade $7.31
Trade Date: 5/8
Shares: 4.1 million
Underwriter(s) Canaccord Genuity, JMP Securities, Oppenheimer & Co.
Co Manager(s) H.C. Wainwright & Co., Noble Life Science Partners
Rating=Subscription Needed
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Portuguese
Russian
Spanish